Xponance Inc. Acquires 91,843 Shares of Pfizer Inc. (NYSE:PFE)

Xponance Inc. grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 11.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 891,024 shares of the biopharmaceutical company's stock after acquiring an additional 91,843 shares during the period. Xponance Inc.'s holdings in Pfizer were worth $25,653,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Worth Asset Management LLC bought a new position in Pfizer in the 1st quarter worth approximately $29,000. Briaud Financial Planning Inc bought a new position in Pfizer in the 3rd quarter worth approximately $30,000. GoalVest Advisory LLC raised its position in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. bought a new position in Pfizer in the 3rd quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC raised its position in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 0.1 %

NYSE PFE traded down $0.04 on Thursday, reaching $25.39. The company had a trading volume of 35,716,955 shares, compared to its average volume of 42,482,289. The firm has a market capitalization of $143.74 billion, a price-to-earnings ratio of 70.51, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.56. The company's fifty day moving average is $27.14 and its 200-day moving average is $28.74.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company's revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.14 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a "buy" rating and a $36.00 target price for the company. Argus cut shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. TD Cowen cut shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Pfizer has an average rating of "Hold" and a consensus price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.